The use of virtual screening and differential scanning fluorimetry for the rapid identification of fragments active against MEK1.

We report the analysis of an in-house fragment screening campaign for the oncology target MEK1. The application of virtual screening (VS) as a primary fragment screening approach, followed by biophysical validation using differential screening fluorimetry (DSF), with resultant binding mode determination by X-ray crystallography (X-ray), is presented as the most time and cost-effective combination of in silico and in vitro methods to identify fragments. We demonstrate the effectiveness of the VS-DSF workflow for the early identification of fragments to both 'jump-start' the drug discovery project and to complement biochemical screening data.

[1]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[2]  M. Jacobson,et al.  Binding-Site Assessment by Virtual Fragment Screening , 2010, PloS one.

[3]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[4]  Woody Sherman,et al.  Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation , 2009, J. Comput. Aided Mol. Des..

[5]  R. Stevens,et al.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.

[6]  D. Lane,et al.  Differential scanning fluorimetry as secondary screening platform for small molecule inhibitors of Bcl-XL , 2009, Cell cycle.

[7]  Hongming Wang,et al.  Virtual fragment screening: an exploration of various docking and scoring protocols for fragments using Glide , 2009, J. Comput. Aided Mol. Des..

[8]  Rutger H A Folmer,et al.  Fragment screening to predict druggability (ligandability) and lead discovery success. , 2011, Drug discovery today.

[9]  S. Chaudhuri,et al.  Differential regulation of the protein tyrosine kinase activity followingiInterleukin-2 (IL-2), Interferron gamma (IFN?) and SRBC administration in brain tumor induced conditions: SRBC acting as a dual potentiator in regulating the cytokine profile , 2004, Cancer biology & therapy.

[10]  C. Schalk-Hihi,et al.  Protein thermal shifts to identify low molecular weight fragments. , 2011, Methods in enzymology.

[11]  G. Greenwood,et al.  Development of a differential scanning fluorimetry based high throughput screening assay for the discovery of affinity binders against an anthrax protein. , 2010, Journal of pharmaceutical and biomedical analysis.

[12]  Irene Nobeli,et al.  SERAPhiC: A Benchmark for in Silico Fragment-Based Drug Design , 2011, J. Chem. Inf. Model..

[13]  Maurizio Pellecchia,et al.  Structure–activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid , 2006, Proceedings of the National Academy of Sciences.

[14]  Alexander D. MacKerell,et al.  Small‐Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics , 2011, ChemMedChem.

[15]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[16]  Roderick E Hubbard,et al.  Experiences in fragment-based lead discovery. , 2011, Methods in enzymology.

[17]  J. Warmus,et al.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.

[18]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[19]  Rob Leurs,et al.  Transforming fragments into candidates: small becomes big in medicinal chemistry. , 2009, Drug discovery today.

[20]  M. Daffé,et al.  Design, synthesis, and biological evaluation of new cinnamic derivatives as antituberculosis agents. , 2011, Journal of medicinal chemistry.

[21]  W. Sellers,et al.  MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.

[22]  D. Case,et al.  Rescoring docking hit lists for model cavity sites: predictions and experimental testing. , 2008, Journal of molecular biology.

[23]  Matthew Paul Gleeson,et al.  QM/MM As a Tool in Fragment Based Drug Discovery. A Cross-Docking, Rescoring Study of Kinase Inhibitors , 2009, J. Chem. Inf. Model..

[24]  S. Knapp,et al.  Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. , 2005, Journal of medicinal chemistry.

[25]  Mathew J Garnett,et al.  Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.

[26]  A. Voet,et al.  Fragment based drug design: from experimental to computational approaches. , 2012, Current medicinal chemistry.

[27]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[28]  Takashi Tsuruo,et al.  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.

[29]  Richard J. Hall,et al.  Docking performance of fragments and druglike compounds. , 2011, Journal of medicinal chemistry.

[30]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[31]  P. Nordlund,et al.  Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination , 2006, Proceedings of the National Academy of Sciences.

[32]  D. Berger,et al.  Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase. , 2004, Molecular cancer therapeutics.

[33]  Robert Kiss,et al.  Virtual Fragment Docking by Glide: a Validation Study on 190 Protein-Fragment Complexes , 2010, J. Chem. Inf. Model..

[34]  Nikhil Wagle,et al.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.